ZyVersa Therapeutics (ZVSA) News Today → Buy this small stock before coming AI Tidal Wave (From Chaikin Analytics) (Ad) Free ZVSA Stock Alerts $4.49 -0.37 (-7.62%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 3:59 PM | benzinga.comZyVersa Therapeutics Stock (NASDAQ:ZVSA), Earnings Estimates, EPS, and RevenueMay 16 at 1:12 AM | investorplace.comZVSA Stock Earnings: ZyVersa Therapeutics Misses EPS for Q1 2024May 15, 2024 | globenewswire.comZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business UpdateMay 14, 2024 | globenewswire.comZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International ConventionMay 11, 2024 | americanbankingnews.comZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Down 96.6% in AprilApril 29, 2024 | msn.comWhat's Going On With ZyVersa Stock?April 29, 2024 | marketbeat.comTrading was temporarily halted for "ZVSA" at 10:04 AM with a stated reason of "LULD pause."April 29, 2024 | finance.yahoo.comZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s DiseaseApril 29, 2024 | globenewswire.comZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer's DiseaseApril 26, 2024 | marketbeat.comTrading was temporarily halted for "ZVSA" at 07:04 PM with a stated reason of "News pending."April 4, 2024 | globenewswire.comZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with DiabetesApril 3, 2024 | benzinga.comZyVersa Therapeutics Stock (NASDAQ:ZVSA), Quotes and News SummaryMarch 27, 2024 | markets.businessinsider.comBuy Rating Affirmed: ZyVersa Therapeutics’ Promising Pipeline and Strategic AdvancementsMarch 25, 2024 | globenewswire.comZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business UpdateMarch 18, 2024 | globenewswire.comZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney DiseaseMarch 14, 2024 | finance.yahoo.comZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024March 14, 2024 | globenewswire.comZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga's Virtual Healthcare Summit 2024 on March 20, 2024March 13, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: ACELYRIN, INC. (SLRN), ZyVersa Therapeutics (ZVSA)February 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for ZyVersa Therapeutics Amid Promising Inflammatory and Metabolic Syndrome TreatmentsFebruary 29, 2024 | globenewswire.comZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat ObesityFebruary 28, 2024 | finance.yahoo.comZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its ComplicationsFebruary 28, 2024 | globenewswire.comZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100's Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its ComplicationsFebruary 26, 2024 | msn.comWhat In The World Is Going On With ZyVersa Therapeutics (ZVSA) Stock?February 26, 2024 | marketbeat.comTrading was temporarily halted for "ZVSA" at 09:02 AM with a stated reason of "LULD pause."February 26, 2024 | marketbeat.comTrading was temporarily halted for "ZVSA" at 09:02 AM with a stated reason of "LULD pause."February 26, 2024 | marketbeat.comTrading was temporarily halted for "ZVSA" at 09:02 AM with a stated reason of "LULD pause."February 26, 2024 | investorplace.comWhy Is ZyVersa Therapeutics (ZVSA) Stock Up 37% Today?February 22, 2024 | finance.yahoo.comZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic OptionFebruary 22, 2024 | globenewswire.comZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic OptionFebruary 14, 2024 | finance.yahoo.comZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological DiseasesFebruary 14, 2024 | globenewswire.comZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological DiseasesFebruary 7, 2024 | finance.yahoo.comZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key MilestonesJanuary 31, 2024 | finance.yahoo.comZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 DiabetesJanuary 24, 2024 | finance.yahoo.comZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer’s DiseaseJanuary 17, 2024 | msn.comWhy Is Inflammatory Disease-Focused ZyVersa Therapeutics Stock Trading Higher Today?January 17, 2024 | finance.yahoo.comZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain MetastasisJanuary 10, 2024 | finance.yahoo.comZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on Benzinga All AccessJanuary 4, 2024 | finance.yahoo.comZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital MarketsJanuary 3, 2024 | finance.yahoo.comZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024December 22, 2023 | benzinga.comThis Biotech Is Targeting Indications Worth $70 BillionDecember 18, 2023 | finance.yahoo.comZyVersa Therapeutics’ CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During “J.P. Morgan Week 2024”December 16, 2023 | markets.businessinsider.comBuy Rating Affirmed for ZyVersa Therapeutics Amid Promising Clinical Trials and Solid Financial PositionDecember 16, 2023 | msn.comZyVersa Therapeutics (ZVSA) Price Target Increased by 860.00% to 24.48December 14, 2023 | finance.yahoo.comZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200December 14, 2023 | finance.yahoo.comZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200December 8, 2023 | uk.finance.yahoo.comZyVersa Therapeutics, Inc. (ZVSA)December 7, 2023 | finance.yahoo.comZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 DiabetesDecember 7, 2023 | marketbeat.comTrading was temporarily halted for "ZVSA" at 11:12 AM with a stated reason of "LULD pause."December 7, 2023 | marketwatch.comZyVersa Therapeutics Shares Slide Premarket After OfferingDecember 7, 2023 | markets.businessinsider.comWhy Is Cerevel Therapeutics (CERE) Stock Up 12% Today? Get ZyVersa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVSA and its competitors with MarketBeat's FREE daily newsletter. Email Address [URGENT] DO NOT Touch These AI Stocks! (Ad)Artificial intelligence stocks are carrying the market. One of them, Nvidia, recently became the seventh company ever to hit a $1 trillion market cap. But is this AI rally over? Click here for our #1 AI Stock for 2024 and Beyond ZVSA Media Mentions By Week ZVSA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ZVSA News Sentiment▼-0.780.42▲Average Medical News Sentiment ZVSA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ZVSA Articles This Week▼52▲ZVSA Articles Average Week Get ZyVersa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVSA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SEEL News SNGX News EVOK News ENSC News GOVX News PTPI News CYCC News ALZN News XCUR News BCEL News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ZVSA) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaMissed NVDA? Buy this AI stock NOWChaikin AnalyticsUrgent Nvidia WarningAltimetryCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMost important medical advance in 100 yearsThe Oxford ClubNext President (Not Trump. Not Biden.)The Freeport SocietyCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceProtect Your Bank Account Before It’s Too LateWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZyVersa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.